Integrating biosensors, that convert a biological response into an electrical signal, with CRISPR/Cas technology, can enhance the detection of specific cancer-related genetic sequences and identify mutations in oncogenes such as KRAS and EGFR, and tumor suppressor genes, such as TP53 [76]. This evidence concerns the gene TP53 and cancer.